Stop TB Partnership: Stop TB Partnership’s Global Drug Facility jumpstarts access to new drugs for multidrug-resistant tuberculosis with innovative public-private partnerships
“A new initiative to enable developing countries to access delamanid — one of two new life-saving drugs approved to combat multidrug-resistant (MDR) tuberculosis (TB) — [was on Wednesday] announced by the Stop TB Partnership and Otsuka, the drug’s manufacturer. The innovative public-private partnership will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility, which already supports the USAID donation for bedaquiline — the other recently approved drug for MDR-TB, manufactured by Janssen…” (2/24).